72/100 · Elevated
Manufactured by Allergan, Inc.
Escitalopram Adverse Events: High Serious Reaction Rate and Diverse Safety Profile
264,686 FDA adverse event reports analyzed
Last updated: 2026-05-12
ESCITALOPRAM is a medication tracked in the FDA Adverse Event Reporting System (FAERS), manufactured by Allergan, Inc.. Based on analysis of 264,686 FDA adverse event reports, ESCITALOPRAM has a safety score of 72 out of 100. This score indicates a relatively favorable safety profile, with fewer or less severe adverse events compared to many other tracked medications. The most commonly reported adverse reactions for ESCITALOPRAM include FATIGUE, NAUSEA, DRUG INEFFECTIVE, HEADACHE, DIARRHOEA. This page provides a comprehensive breakdown of reported side effects, safety signals, patient demographics, and AI-powered safety analysis for ESCITALOPRAM.
Escitalopram has a safety concern score of 72 out of 100, placing it in the elevated concern category based on analysis of FDA adverse event data. The FDA has received approximately 264,686 adverse event reports for this medication, which is primarily manufactured by Allergan, Inc..
The most commonly reported adverse events include Fatigue, Nausea, Drug Ineffective. Of classified reports, 67.2% were designated as serious by the FDA, meaning they involved hospitalization, disability, or other significant medical outcomes. Escitalopram reports show a high percentage of serious adverse events, particularly related to mental health and cardiovascular issues.
The most common reactions include fatigue, nausea, and headache, indicating a broad range of potential side effects. Serious reactions such as death, suicidal ideation, and pneumonia are notable, highlighting significant safety concerns.
Patients taking Escitalopram should monitor for the commonly reported side effects and contact their healthcare provider if they experience any unusual symptoms. Escitalopram warnings include potential for serotonin syndrome, drug interactions, and increased risk of suicidal ideation, especially in young adults. This analysis is based on voluntary FDA adverse event reports and should not replace professional medical advice.
Escitalopram received a safety concern score of 72/100 (elevated concern). This is based on a 67.2% serious event ratio across 134,486 classified reports. The score accounts for 264,686 total adverse event reports and 100 distinct reaction types. This elevated score indicates a notable proportion of serious adverse events and warrants careful monitoring.
Adverse event reports by sex: Female: 85,594, Male: 38,528, Unknown: 325. The most frequently reported age groups are age 65 (1,811 reports), age 56 (1,796 reports), age 57 (1,784 reports). These demographics reflect reporting patterns and may not represent the full patient population.
Out of 134,486 classified reports for ESCITALOPRAM:
The FDA classifies an adverse event as “serious” if it results in death, hospitalization, disability, congenital anomaly, or requires intervention to prevent permanent damage.
Demographics reflect voluntary FDA adverse event reporting patterns and may not represent the full patient population.
Escitalopram warnings include potential for serotonin syndrome, drug interactions, and increased risk of suicidal ideation, especially in young adults.
If you are taking Escitalopram, here are important things to know. The most commonly reported side effects include fatigue, nausea, drug ineffective, headache, diarrhoea. While many of these may be mild and temporary, you should contact your healthcare provider if any symptoms are severe or persistent. Monitor for signs of suicidal ideation, especially in the first few weeks of treatment. Be aware of potential drug interactions and inform healthcare providers of all medications being taken. If you experience a serious adverse reaction, seek emergency medical attention immediately or call 911. You can report side effects to the FDA's MedWatch program at 1-800-FDA-1088.
Escitalopram is subject to strict monitoring by the FDA due to its high rate of serious adverse events, particularly in elderly and young adult populations.
The FDA has received approximately 264,686 adverse event reports associated with Escitalopram. These reports come from healthcare professionals, consumers, and manufacturers through the FDA Adverse Event Reporting System (FAERS). Note that the number of reports does not directly indicate the frequency of side effects, as adverse events are voluntarily reported and may be underrepresented.
The most frequently reported adverse events for Escitalopram include Fatigue, Nausea, Drug Ineffective, Headache, Diarrhoea. By volume, the top reported reactions are: Fatigue (9,197 reports), Nausea (9,163 reports), Drug Ineffective (8,599 reports). These figures reflect FDA adverse event reports and may not represent the true incidence rate of these side effects in all patients taking Escitalopram.
Out of 134,486 classified reports, 90,391 (67.2%) were classified as serious and 44,095 as non-serious. The FDA classifies an event as "serious" if it results in death, hospitalization, disability, or other medically significant outcomes. A higher serious-event ratio warrants closer attention but does not necessarily mean the drug is unsafe.
Adverse event reports for Escitalopram break down by patient sex as follows: Female: 85,594, Male: 38,528, Unknown: 325. This distribution reflects reporting patterns rather than actual risk differences between groups. Reporting rates can be influenced by prescribing patterns, disease demographics, and reporting behavior.
The most frequently reported age groups for Escitalopram adverse events are: age 65: 1,811 reports, age 56: 1,796 reports, age 57: 1,784 reports, age 61: 1,776 reports, age 63: 1,775 reports. Age-related reporting patterns can reflect both the demographics of the patient population and potential age-related susceptibility to certain side effects.
The primary manufacturer associated with Escitalopram adverse event reports is Allergan, Inc.. Multiple manufacturers may produce generic versions of this drug. The manufacturer listed reflects the most frequently reported brand in FDA adverse event data.
Beyond the most common reactions, other reported adverse events for Escitalopram include: Anxiety, Dizziness, Depression, Off Label Use, Pain. Less common side effects can still be clinically significant. Patients should report any unusual symptoms to their healthcare provider.
You can report adverse events from Escitalopram to the FDA through their MedWatch program at www.fda.gov/medwatch, by calling 1-800-FDA-1088, or by completing Form FDA 3500. Healthcare professionals, consumers, and manufacturers can all submit reports. Reporting helps the FDA monitor drug safety after approval.
Escitalopram has a safety concern score of 72 out of 100 (elevated concern). This score is calculated from the ratio of serious to non-serious adverse events, the diversity of reported reactions, and the overall volume of reports relative to usage. Escitalopram reports show a high percentage of serious adverse events, particularly related to mental health and cardiovascular issues.
Key safety signals identified in Escitalopram's adverse event data include: High percentage of serious adverse events (67.2%). Significant reports of suicidal ideation and death. Diverse range of reactions including cardiovascular, gastrointestinal, and mental health issues. These signals are derived from patterns in FDA reports and should be discussed with a healthcare provider for personalized assessment.
Escitalopram warnings include potential for serotonin syndrome, drug interactions, and increased risk of suicidal ideation, especially in young adults. Always inform your healthcare provider about all medications, supplements, and over-the-counter drugs you are taking before starting Escitalopram.
Monitor for signs of suicidal ideation, especially in the first few weeks of treatment. Be aware of potential drug interactions and inform healthcare providers of all medications being taken.
Escitalopram has 264,686 adverse event reports on file with the FDA. The most common reactions include fatigue, nausea, and headache, indicating a broad range of potential side effects. The volume of reports for Escitalopram reflects both the drug's usage level and the vigilance of the reporting community.
Escitalopram is subject to strict monitoring by the FDA due to its high rate of serious adverse events, particularly in elderly and young adult populations. For the most current regulatory information, check the FDA's drug labeling database or consult your pharmacist.
Explore other medications manufactured by Allergan, Inc. and compare their safety profiles:
The following drugs share commonly reported adverse reactions with ESCITALOPRAM:
Drugs related to ESCITALOPRAM based on therapeutic use, drug class, or shared indications: